PO.5.117 Serum atherogenicity in women with untreatedlupusnephritis

BackgroundSystemic lupus erythematosus(SLE) is associated with an unexplained increase cardiovascular risk.The nature of the factors that contribute to progression of atherosclerosiswere identified using the method for determining the atherogenicity of blood serum in cell culturein cell culture (in vitro). The term ‘atherogenicity’ is meant as the ability of the serum and/or its components to induce intracellular accumulation of cholesterol in cultured cells.ObjectiveTo determine atherogenicity of blood serum in womenwith untreatedlupus nephritis(LN),and to compare it withuntreatedSLE women without LN, andin healthy women.MethodsFifteenwomen(median age 29 [22;39] years) with active untreated LN (mediandisease duration 15 [3;45]months;were enrolled in group 1 the study. Twenty two SLE women without LN(median age 31[21;41] years, median disease duration 10[5;38] months;were included in group2.SLADAI 2Kwas higher in patients of group 1 (21 [12;39]) compared to patients of group 2 (12[6;18], p